DATE : 16-03-13 12:27
New drug-eluting stents to prevent stent thrombosis and restenosis for acute myocardial infarction: from the experience of Korean acute myocardial infarction registry.
|
|
WRITER :
stent
HIT : 1,383
|
B48._SPIE_2012;8548_3_1-7..pdf (178.0K) [0] DATE : 2016-03-13 12:27:49 |
B48. Bae IH, Jeong MH; New drug-eluting stents to prevent stent thrombosis and restenosis for acute myocardial infarction: from the experience of Korean acute myocardial infarction registry. SPIE 2012;8548(3)1-7.
(Abstract)
Drug-eluting stents (DES) are superior to bare metal stents (BMS) in reducing restenosis rates across a wide range of patients and lesion subsets. This study presented the investigation of one-year clinical follow-up were registered in 52 primary percutaneous coronary intervention sites in Korea, and pre-clinical results of various drug-coated stent fabricating with many other coating approaches on physiological parameters, Based on our clinical study adverse cardiac events were 17.4 % after DES implantation, which was significantly lower compared with 24.9% of BMS implanted patients. As assumption above outcome, it well repays research and development in new DES. Our research group carefully chooses abciximab, alpha-lipoic acid, heparin / dopamine, inhibitors in cell signal cascade were employed as coating drug. These drug candidates were coated on BMS surface by various methods such as TiO2 film deposited by plasma enhanced chemical vapor deposition, ultrasonic sprayer / simple-dip coating, or bio-inspired natural binding technique. In vitro and in vivo results of these new DES fabricated by our research group have showed superior outcomes compare to BMS on physiological parameters such as inflammation score, re-endothelialization, preventing neointema or thrombosis etc. These results are promising safer and more effective to overcome the limitation of DES. © (2012) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
|
|